Roberto Esquivel-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberto Esquivel-García has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Garcia-Perez
Facultad de Químico-Farmacobiología, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico
6 shared publications - Alejandra Ochoa-Zarzosa
Centro Multidisciplinario de Estudios en Biotecnología—FMVZ, Universidad Michoacana de San Nicolás de Hidalgo, Tarimbaro 58893, Michoacan, Mexico
3 shared publications Manuel García-Pérez
2 shared publications- Alain Raimundo Rodríguez Orozco
Facultad de Ciencias Médicas y Biológicas “Dr. Ignacio Chávez”, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58020, Mexico
1 shared publication Alain Raimundo Rodríguez-Orozco
Facultad de Ciencias Médicas y Biológicas. Universidad Michoacana de San Nicolás de Hidalgo, Michoacán, México
1 shared publicationAlejandra Ochoa-Zarzosa
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 14 (2)
Adverse events and potential herb-drug interactions of plants used for psoriasis: A systematic review
Context: Medicinal plants have been widely used for psoriasis management for centuries. However, their safety profiles remain insufficiently documented. Aims: To systematically evaluate adverse events (AEs) and potential pharmacokinetic interactions of antipsoriatic herbal treatments. Methods: A PRISMA-compliant review was conducted using PubMed, Cochrane, Google Scholar, Web of Science, and Scopus databases (January 2015-December 2022). Clinical trials, case reports, and ethnomedicinal studies reporting AEs of single plant antipsoriatic preparations were included. CONSORT criteria for herbal medicines were applied to assess study quality. Results: Eleven studies covering nine herbal treatments were included. While most of reported AEs were mild, severe cases involving Indigo naturalis, Psoralea corylifolia, and Ranunculus arvensis were documented. Several herbal metabolites (indirubin, psoralen, curcumin, triptolide) showed potential pharmacokinetic interactions with conventional drugs. Conclusions: While generally well tolerated, antipsoriatic herbal therapies can induce mild to severe AEs and may alter drug metabolism. Long-term, high-quality randomized trials are needed to establish their safety profile.
- 1 March 2026
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 14 (2)
Open AccessAdverse events and potential herb-drug interactions of plants used for psoriasis: A systematic review
Context: Medicinal plants have been widely used for psoriasis management for centuries. However, their safety profiles remain insufficiently documented. Aims: To systematically evaluate adverse events (AEs) and potential pharmacokinetic interactions of antipsoriatic herbal treatments. Methods: A PRISMA-compliant review was conducted using PubMed, Cochrane, Google Scholar, Web of Science, and Scopus databases (January 2015-December 2022). Clinical trials, case reports, and ethnomedicinal studies reporting AEs of single plant antipsoriatic preparations were included. CONSORT criteria for herbal medicines were applied to assess study quality. Results: Eleven studies covering nine herbal treatments were included. While most of reported AEs were mild, severe cases involving Indigo naturalis, Psoralea corylifolia, and Ranunculus arvensis were documented. Several herbal metabolites (indirubin, psoralen, curcumin, triptolide) showed potential pharmacokinetic interactions with conventional drugs. Conclusions: While generally well tolerated, antipsoriatic herbal therapies can induce mild to severe AEs and may alter drug metabolism. Long-term, high-quality randomized trials are needed to establish their safety profile.
- Open Access
- 10 December 2024
- Published by Universidad Michoacana de San Nicolas de Hidalgo in Milenaria, Ciencia y arte
- No. 24,p. 31-33
Cuachalalate (Amphipterygium adstringens): un viaje desde la medicina ancestral hasta la actualidad
En el contexto de la medicina tradicional y la investigación científica, las plantas medicinales desempeñan un papel crucial, reflejando la riqueza del conocimiento ancestral. El cuachalalate (Amphipterygium adstringens), es una especie endémica de México, que ha sido ampliamente aprovechada desde épocas prehispánicas, destacando su uso medicinal y su aplicación artesanal. Reconocido por sus propiedades adstringentes, cicatrizantes, antibióticas, antimaláricas y antiinflamatorias es una especie fascinante que nos lleva de la mano desde los tiempos antiguos hasta las modernas tendencias farmacológicas. Acompáñanos a descubrirlo.
- 10 December 2024
- Published by Universidad Michoacana de San Nicolas de Hidalgo in Milenaria, Ciencia y arte
- No. 24,p. 31-33
Open AccessCuachalalate (Amphipterygium adstringens): un viaje desde la medicina ancestral hasta la actualidad
En el contexto de la medicina tradicional y la investigación científica, las plantas medicinales desempeñan un papel crucial, reflejando la riqueza del conocimiento ancestral. El cuachalalate (Amphipterygium adstringens), es una especie endémica de México, que ha sido ampliamente aprovechada desde épocas prehispánicas, destacando su uso medicinal y su aplicación artesanal. Reconocido por sus propiedades adstringentes, cicatrizantes, antibióticas, antimaláricas y antiinflamatorias es una especie fascinante que nos lleva de la mano desde los tiempos antiguos hasta las modernas tendencias farmacológicas. Acompáñanos a descubrirlo.
- 10 April 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (3) , 290-301
Updated view of tars for psoriasis: what have we learned over the last decade?
Tars are one of the most effective, unknown, and oldest therapies for psoriasis. They include coal tar (CT) and biomass‐derived products. These treatments, particularly the CT, have proven to be cost‐effective with long remission times compared to other systemic or topical treatments. However, they have hardly evolved in recent years, as they are not well‐embraced by clinicians or patients because of concerns regarding cosmesis and safety. This review summarizes current knowledge about the chemical characterization, mechanism of action, toxicity, and clinical studies supporting the use of tars for psoriasis over the last decade. Trends within these above aspects are reviewed, and avenues of research are identified. CT is rich in polycyclic aromatic hydrocarbons, whereas biomass‐derived tars are rich in phenols. While the activation of the aryl hydrocarbon receptor is involved in the antipsoriatic effect of CT, the mechanism of action of biomass‐derived products remains to be elucidated. No conclusive evidence exists about the risk of cancer in psoriasis patients under CT treatment. Large, randomized, double‐blind, controlled clinical trials are necessary to promote the inclusion of tars as part of modern therapies for psoriasis.
- 10 April 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (3) , 290-301
Updated view of tars for psoriasis: what have we learned over the last decade?
Tars are one of the most effective, unknown, and oldest therapies for psoriasis. They include coal tar (CT) and biomass‐derived products. These treatments, particularly the CT, have proven to be cost‐effective with long remission times compared to other systemic or topical treatments. However, they have hardly evolved in recent years, as they are not well‐embraced by clinicians or patients because of concerns regarding cosmesis and safety. This review summarizes current knowledge about the chemical characterization, mechanism of action, toxicity, and clinical studies supporting the use of tars for psoriasis over the last decade. Trends within these above aspects are reviewed, and avenues of research are identified. CT is rich in polycyclic aromatic hydrocarbons, whereas biomass‐derived tars are rich in phenols. While the activation of the aryl hydrocarbon receptor is involved in the antipsoriatic effect of CT, the mechanism of action of biomass‐derived products remains to be elucidated. No conclusive evidence exists about the risk of cancer in psoriasis patients under CT treatment. Large, randomized, double‐blind, controlled clinical trials are necessary to promote the inclusion of tars as part of modern therapies for psoriasis.
- Open Access
- 3 October 2018
- Published by Instituto de Ecologia, A.C. in Acta Botanica Mexicana
- Vol. 125 (125) , 95-132
Ethnomedicinal plants used for the treatment of dermatological affections on the Purépecha Plateau, Michoacán, Mexico
Background and Aims: Inhabitants of the Purépecha Plateau preserve an excellent ancestral knowledge on medicinal plants used for dermatological affections, which has not been documented. An ethnopharmacological survey was carried out in this region to gather information on the use of medicinal plants and herbal preparations for treating dermatological affections, to disseminate the Purépecha indigenous knowledge and identifying promising plants for developing new formulations for cutaneous conditions.Methods: The study was conducted in the 21 municipalities that compose the Purépecha Plateau. A total of 86 local inhabitants (62 women and 24 men) were interviewed. The data were quantitatively analyzed through the determination of the use value, fidelity level and informant consensus factor.Key results: A total of 97 plant species belonging to 47 families were documented for treating 19 dermatological conditions on the Purépecha Plateau. Asteraceae was the leading family among the collected medicinal plants (20.61%), followed by Lamiaceae (13.40%) and Solanaceae (5.15%). The largest number of plants was used for the treatment of cuts (40.20%), skin inflammation (37.11%) and rash (37.11%). The aerial parts were the most commonly used (34.75%). The medicinal plant species with larger use values were Heterotheca inuloides (0.53), Aloe vera (0.37) and Oenothera rosea (0.21). The comparison of results with ethnomedicinal literature worldwide revealed that 8.25% of plants used on the Purépecha Plateau were recorded for the first time for the treatment of dermatological affections.Conclusions: This study provides new information on medicinal plants used on the Purépecha Plateau to treat cutaneous diseases. Future pharmacological and toxicological investigations are required to demonstrate the efficacy and safety of these species for treating dermatological affections.
- 3 October 2018
- Published by Instituto de Ecologia, A.C. in Acta Botanica Mexicana
- Vol. 125 (125) , 95-132
Open AccessEthnomedicinal plants used for the treatment of dermatological affections on the Purépecha Plateau, Michoacán, Mexico
Background and Aims: Inhabitants of the Purépecha Plateau preserve an excellent ancestral knowledge on medicinal plants used for dermatological affections, which has not been documented. An ethnopharmacological survey was carried out in this region to gather information on the use of medicinal plants and herbal preparations for treating dermatological affections, to disseminate the Purépecha indigenous knowledge and identifying promising plants for developing new formulations for cutaneous conditions.Methods: The study was conducted in the 21 municipalities that compose the Purépecha Plateau. A total of 86 local inhabitants (62 women and 24 men) were interviewed. The data were quantitatively analyzed through the determination of the use value, fidelity level and informant consensus factor.Key results: A total of 97 plant species belonging to 47 families were documented for treating 19 dermatological conditions on the Purépecha Plateau. Asteraceae was the leading family among the collected medicinal plants (20.61%), followed by Lamiaceae (13.40%) and Solanaceae (5.15%). The largest number of plants was used for the treatment of cuts (40.20%), skin inflammation (37.11%) and rash (37.11%). The aerial parts were the most commonly used (34.75%). The medicinal plant species with larger use values were Heterotheca inuloides (0.53), Aloe vera (0.37) and Oenothera rosea (0.21). The comparison of results with ethnomedicinal literature worldwide revealed that 8.25% of plants used on the Purépecha Plateau were recorded for the first time for the treatment of dermatological affections.Conclusions: This study provides new information on medicinal plants used on the Purépecha Plateau to treat cutaneous diseases. Future pharmacological and toxicological investigations are required to demonstrate the efficacy and safety of these species for treating dermatological affections.
- 13 July 2018
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 154 (4) , 502-508
La psoriasis: de la investigación básica y clínica al desarrollo de nuevos tratamientos
Psoriasis is an incurable cutaneous disease that affects 2.9% of the Mexican population, and it is therefore important for the impact of translational medicine on the development of anti-psoriatic drugs to be analyzed. In this review, current etiopathogenic concepts of the disease are discussed, and articles on drugs under development published between 2005 and 2017 are reviewed; in addition, a critical analysis on future perspectives for the development new treatments is presented. The use of translational medicine bi-directional strategies of has allowed to significantly increase the number of available anti-psoriatic therapies. Eighteen new investigational drugs were found. Characterization of antigens responsible for immune activation, identification of predictive biomarkers with pharmacologic efficacy, and the development of more representative disease models, as well as the integration of pharmacogenomic aspects to translational medicine strategies were identified as relevant aspects that should be incorporated in the development of new therapeutic options.
- 13 July 2018
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 154 (4) , 502-508
La psoriasis: de la investigación básica y clínica al desarrollo de nuevos tratamientos
Psoriasis is an incurable cutaneous disease that affects 2.9% of the Mexican population, and it is therefore important for the impact of translational medicine on the development of anti-psoriatic drugs to be analyzed. In this review, current etiopathogenic concepts of the disease are discussed, and articles on drugs under development published between 2005 and 2017 are reviewed; in addition, a critical analysis on future perspectives for the development new treatments is presented. The use of translational medicine bi-directional strategies of has allowed to significantly increase the number of available anti-psoriatic therapies. Eighteen new investigational drugs were found. Characterization of antigens responsible for immune activation, identification of predictive biomarkers with pharmacologic efficacy, and the development of more representative disease models, as well as the integration of pharmacogenomic aspects to translational medicine strategies were identified as relevant aspects that should be incorporated in the development of new therapeutic options.